Anisha Wharton serves as Head of Regulatory Affairs at AVEO and brings more than 16 years of global regulatory leadership to support the development, registration and life-cycle management of biologics and pharmaceutical products. Prior to joining AVEO in 2021, Ms. Wharton served as Director, Global Regulatory Affairs – Oncology at Merck & Co., Inc. where she served as the Global Regulatory Lead for early and late-stage clinical development programs for advanced metastatic tumors, women’s cancers, melanoma, and multiple myeloma. While at Merck, Ms. Wharton led a global regulatory team responsible for the approval of a new dosing regimen of KEYTRUDA® across all approved adult indications in over 35 countries. Prior to Merck, she served in global Regulatory Affairs roles of increasing complexity and responsibility at Nektar Therapeutics, InterMune, Inc. (acquired by Roche), InSite Vision, Inc. (acquired by Sun Pharma), and Genentech, Inc. She helped lead a cross functional team in the approval of ESBRIET® and AZASITE®, as well as the development of a global regulatory intelligence database. Ms. Wharton earned her Bachelor of Science degree from Clark Atlanta University and her Master of Business Administration degree from the University of San Francisco School of Management.
Michael has extensive experience counseling life sciences companies to achieve clinical and commercial goals while responsibly managing compliance and enforcement risks. He previously held in-house Legal and Compliance positions at PDL BioPharma, Mylan and Dendreon. Michael began his legal career with the FDA Drug and Biotechnology practice at an international law firm in Washington, DC. Prior to his career as an attorney, Michael was a marketer with Procter & Gamble and Bristol-Myers Squibb. Michael earned Juris Doctor and Master of Public Health degrees from the University of Virginia and a Bachelor of Arts degree from the University of Notre Dame.
Noelia Rycerz brings more than 17 years of global drug development experience to her role at Aveo Oncology. Ms. Rycerz has held roles of increasing seniority in Clinical Operations and Program Management at Amgen Inc., Pfizer Inc., and Odonate Therapeutics, Inc. She led and executed clinical phase 1 – 3 clinical trials in varying therapeutics areas including oncology, rheumatology and cardiovascular disease. During her time at Amgen Inc. as a Program Manager, she supported CMC, Regulatory and Safety Affairs to ensure delivery of marketing applications leading to approval of Corlanor®. While at Pfizer, Ms. Rycerz was accountable for oversight of pivotal clinical trials and support of regulatory inspections leading to marketing application approvals for Xeljanz®, Besponsa® and Daurismo®. Ms. Rycerz received a Bachelors of Science at Boston University.
Ganesh Rajaratnam serves as AVEO Oncology’s Vice President of Business Analytics. In this role, Mr. Rajaratnam is responsible for AVEO’s enterprise-wide Business Analytics, including Commercial Analytics, Commercial Operations, Market Insights and Omnichannel Strategy and Operations.
Mr. Rajaratnam has more than 15 years of diverse experience spanning multiple therapeutic areas within the biopharmaceutical and healthcare sectors. Before joining AVEO in 2020, he served as the Director of Field Operations at AMAG Pharmaceuticals where he was responsible for all aspects of field operations, including supporting go-to-market modeling and launch execution for bremelanotide. Prior to this role, Mr. Rajaratnam held roles of increasing responsibility in finance and various rotational positions spanning investor relations, sales, managed care, and field operations at Alkermes. Earlier in his career, Mr. Rajaratnam held positions of increasing responsibility in Finance at Brigham and Women’s Hospital.
Mr. Rajaratnam earned a bachelor’s degree in Computer Engineering, with a minor in Mathematics from the University of Miami (FL) and a Master of Business Administration from Suffolk University Sawyer Business School.
Kevin Peacock currently serves as AVEO’s Senior Vice President of Marketing. Prior to joining AVEO, he served as both the Vice President, New Product Planning and Business Development at Lycera where he was leading the early commercialization process for Lycera’s novel immune-oncology compounds and in 2015 completed an exclusive strategic collaboration and license with Celgene resulting in $100M in non-dilutive financing. Mr. Peacock also previously served as Vice President, Global Marketing and Business Analytics at Dendreon, where he led the launch of Provenge® in select European countries and managed the US Business Analytics team. Mr. Peacock was Senior Director and Product Champion for Savient Pharmaceuticals while working on Krystexxa® and previously served as Senior Director of New Product Planning at Allos Therapeutics. Prior to that, Mr. Peacock held various roles on the ERBITUX® brand team while at ImClone Systems. Mr. Peacock’s has extensive experience in the oncology commercialization process including marketing, market research, new product planning and product development on the R&D side. Mr. Peacock earned his Bachelor of Administration in Finance and Risk Management from Temple University.
Manoj Patel has more than 20 years of experience in the pharmaceutical industry, over 15 of which are directly in the development of oncologic treatments and joins AVEO as Vice President of Program Management. Prior to joining AVEO’s management team, Dr. Patel led the development of several biologics programs as a Project Leader within Teva’s specialty pharma group. Prior to Teva, he held several senior level positions within Project and Program Management as well as Customer Solutions at PRA Health Sciences (now part of ICON) and IQVIA. During his tenure at these CROs, Dr. Patel oversaw the development of oncology treatments for several major pharmaceutical and biotech clients. Prior to IQVIA, he worked at GlaxoSmithKline for more than 10 years across multiple functions that included Clinical Development, Medical Affairs and Project Management. Dr. Patel was also Sr. Director of Program and Alliance Management at ImClone Systems and was involved in the process leading to the ultimate sale of the company to Eli Lilly. Dr. Patel received BS degrees in Chemistry and Pharmacy from the University of North Carolina at Chapel Hill and a Doctorate of Pharmacy from Campbell University.
Greg Oehrtman brings over 20 years of Drug Development experience to his role returning to AVEO after 8 years. Dr. Oehrtman has held roles of increasing seniority in Drug Development and Manufacturing at Quintiles/Catalent, Amylin, Stealth Biotherapeutics, and Dicerna. He has led both drug substance and product development and manufacturing from early pre-clinical to commercial validations, supporting development of Fast Acting Advil, Advil PM, Bydureon, FOTIVDA, Elamipretide, and Nedosiran. While in these roles, he has managed product development of small molecules, peptides, and antibodies as oral and sterile injectable along with combination device development. Dr. Oehrtman received his Ph.D in Chemical Engineering from Massachusetts Institute of Technology.
Jason Noto brings over 20 years of broad commercial leadership experience to his role as Senior Vice President of Market Access at AVEO Oncology. Prior to joining AVEO, Jason served as Vice President at 1798 Consultants, a strategic market access consultancy specializing in integrated channel strategy, patient support services (HUB), payer contract development and assessment, financial impact analysis, and related Access functions. Earlier, Jason served as Senior Director of Market Access Strategy and Payer Marketing at Amag Pharmaceuticals, leading Payer marketing efforts across all business units totaling >$600M in revenue in 2019.
Prior to his tenure at Amag Pharmaceuticals, Mr. Noto held various launch, in-line, and multi-channel marketing leadership roles of increasing responsibility at Sunovion Pharmaceuticals, Alkermes, and Bristol-Myers Squibb Company. During his career, Mr. Noto has had responsibility for the US commercial launch of various specialty products in oncology, immunology, CNS, & ultra-orphan disease states. Mr. Noto received a B.S. in Business Administration from Le Moyne College and an M.B.A. in finance from the Carroll School of Management at Boston College.
Barbara Natke serves as Vice President of Business Development and bringing more than 20 years of Biotech/Pharma experience to AVEO. Prior to joining AVEO, Dr. Natke served as the Vice President of Business Development at Samyang Biopharm, USA where she was responsible for creating a pipeline of transformative oncology therapies for the newly established US entity of the Samyang Holdings Corporation. Prior to Samyang, Dr. Natke served in a variety of roles of increasing responsibility in the Shire/Takeda organization including Scientific Director and Due Diligence Lead. Before making the transition to the business side of the Pharma industry, Barbara spent 8 years running laboratory groups at Genzyme/Sanofi following her post-doctoral studies at the Massachusetts Institute of Technology. Dr. Natke holds a PhD in Biochemistry from Boston University School of Medicine and an MBA from Babson College.
Erick Lucera brings to AVEO over twenty years of financial, operational, and investment experience in the biotechnology and medical device industries. He most recently served as chief financial officer of Valeritas, a publicly traded commercial-stage medical technology company focused on developing solutions for people with diabetes, where he led the company through multiple successful public offerings. Prior to Valeritas, Mr. Lucera served as the chief financial officer, treasurer, and secretary of Viventia Bio (acquired by Eleven Biotherapeutics, Inc., now Sesen Bio), a biotechnology company focused on developing targeted protein therapeutics for the treatment of cancer. He also previously served as vice president, corporate development at Aratana Therapeutics, a veterinary biopharmaceutical company, where he helped grow the company’s product pipeline through a series of acquisitions and in-licensing transactions financed through five public and private offerings of nearly $250 million. Previously, Mr. Lucera was vice president, corporate development at Sunshine Heart (now CHF Solution), a medical device manufacturer.
Prior to Sunshine Heart, Mr. Lucera spent over 15 years in investment management as a healthcare analyst at Eaton Vance, the portfolio manager of the Triathlon Life Sciences Fund at Intrepid Capital, and as head of the healthcare research team at Independence Investments. He began his career as a staff auditor and accountant at Price Waterhouse & Co. (now PwC). Mr. Lucera holds a CPH from Harvard University, an MS from Boston College, an MBA from Indiana University Bloomington, and a BS in accounting from the University of Delaware. Mr. Lucera currently holds a CFA designation. Mr. Lucera previously held CMA and CPA designations, which are expired.